



ANNUAL REPORT

OF THE

Anti-Infective Drugs Advisory Committee

for the period

October 1, 2003 through September 30, 2004

FUNCTION

The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and make appropriate recommendations to the Commissioner of Food and Drugs.

MEMBERSHIP

A roster of members is attached.

MEETINGS

The committee met five times during the reporting period in Gaithersburg, Maryland and Rockville, Maryland.

The dates of those meetings were October 28 & 29, 2003, October 29 & 30, February 2, 2004, February 3 & 4, and June 9, 2004.

The meeting on October 28, 2003, included a closed session to permit discussion or presentation of trade secret or confidential commercial information or disclosure would constitute a clearly unwarranted invasion of personal privacy.

ACCOMPLISHMENTS

October 28-29, 2003: On October 28, 2003, the Anti-Infective Drugs Advisory Committee began with a closed session. The meeting was closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b (c) (4)). Following the closed session, the committee discussed clinical trial design issues for demonstrating the safety and efficacy of antimicrobials in the treatment of diabetic foot infections. The committee offered responses to agency questions to include: 1) the definition of “diabetic foot infection”, 2) considerations for clinical trials for ruling out osteomyelitis in patients in trials of diabetic foot infections, 3) how to determine drug efficacy for the diabetic foot infection in the setting of osteomyelitis and whether such patients should be considered clinical cures or failures, and 4) how to define clinical success or failure in patients in a clinical trial of diabetic foot infections. The Agency’s questions generated productive discussions of the issues, but the Committee was unable to reach consensus. Agency action: the agency obtained information from the advisory committee to revise the “Uncomplicated and Complicated Skin and Skin Structures Guidance” to include information on diabetic foot infections. On October 29, 2003, the Committee discussed clinical trial design of antimicrobials in the treatment of acute bacterial sinusitis. The agency obtained information from the advisory committee for review of the “Acute Bacterial Sinusitis Guidance Document”. The committee offered recommendations on the following: 1) how to ensure that patients in clinical trials of acute bacterial sinusitis have bacterial disease, 2) the methods of obtaining microbiologic data including sinus punctures and nasal endoscopy, 3) the strengths and limitations of placebo-controlled trials and non-inferiority trials, 4) determining a non-inferiority margin in non-inferiority trials for this indication, 5) the strengths and limitations of comparative microbiologic data, and 6) the issues of measuring outcomes in patients in trials of acute bacterial sinusitis, to include the measurement of time-to-resolution of symptoms as an endpoint compared to fixed endpoints. Agency action: This guidance document entitled “Acute bacterial Sinusitis- Developing Drugs for Treatment” has been rewritten and is currently undergoing internal agency review.

October 29-30, 2003: On October 29, 2003, the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee met to discuss the clinical risk management of hypothalamic pituitary adrenal (HPA) axis suppression in children with Atopic Dermatitis being treated with Topical Corticosteroids and the agency reported to the Subcommittee on Adverse Event Reporting as mandated in section 17 of the Best Pharmaceuticals for Children Act (BCPA). The products discussed during this portion of the meeting included ZYRTEC (cetirizine), BUSULFEX (busulfan), COZAAR (losartan), NOLVADEX (tamoxifen), ACCUPRIL (quinapril), and SERZONE (nefazodone).

The Subcommittee felt that use of topical corticosteroids was a relevant concern for pediatric patients. Several risk management approaches were discussed to include; the conduct of additional studies in children, to include, epidemiological studies relating to steroid exposure and effect on risk, studies to look at cortisol levels in patients under conditions of high stress, educational items that provide practical information such as that included in the Patient Package Insert, and education materials that provide information on issues on the topic that are actively being discovered. Agency action: The agency is taking the advisory committee recommendations under consideration.

On October 30, 2003, the Subcommittee met to discuss how to approach long-term monitoring for cancer occurrence among patients treated for atopic dermatitis with topical immunosuppressants. The Subcommittee felt that education and training, additional studies and possible labeling changes may be necessary to address long term monitoring for cancer occurrence among patients treated for atopic dermatitis with topical immunosuppressants. Agency action: The agency is taking the advisory committee recommendations under consideration.


February 2, 2004: On February 2, 2004, the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee met with the Psychopharmacologic Drugs Advisory Committee to discuss reports of the occurrence of suicide (both suicidal ideation and suicide attempts) in clinical trials for various anti-depressant drugs in pediatric patients with major depressive disorder (MDD). The Committee considered optimal approaches to the analysis of data from these trials, and the results of analyses conducted to date, with regard to the question of what regulatory action may be needed pertinent to the clinical use of these products in pediatric patients. The Committee also considered further research was needed to address questions on the topic. Agency action: The agency had a follow-up joint advisory committee meeting with participation by the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee on September 13 and 14, 2004, to discuss reports of the occurrence of suicide (both suicide ideation and suicide attempts) in clinical trials for various antidepressant drugs in pediatric patients with major depressive disorder and other psychiatric disorders. This meeting was announced in the Federal Register of August 4, 2004 (69 FR 47157-47158).

February 3-4, 2004: On February 3, 2004, the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee met and the agency reported to the Subcommittee on Adverse Event Reporting as mandated in Section 17 of the Best Pharmaceuticals for Children Act (BPCA). The products reported were Paxil (paroxetine), Celexa (citalopram), Pravachol (pravastatin), and Navelbine (vinorelbine). The Subcommittee then discussed the use of imaging drugs in conjunction with cardiac imaging procedures in the pediatric population. On February 4, 2004, the Subcommittee met to continue the discussion of the use of imaging drugs in conjunction with cardiac imaging procedures in the pediatric population. Agency action: The agency is taking the advisory committee recommendations under consideration.

June 9, 2004: On June 9, 2004, the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee met and the agency reported to the Committee on the adverse event reporting as mandated in section 17 of the Best Pharmaceuticals for Children Act. The products discussed included HYCAMTIN (topotecan), TEMODAR (temozolomide), EFFEXOR (venlafaxine), MONOPRIL (fosinopril), ALLEGRA (fexofenadine), DURAGESIC (fentanyl), CILOXAN (ciprofloxacin), and VIGAMOX (moxifloxacin). Following this, the agency provided an update on neonatal withdrawal syndrome and congenital eye malformations reported in infants whose mothers used selective serotonin reuptake inhibitors (SSRIs) during pregnancy. An overview of the Pediatric Research Equity Act, which was signed into law on December 3, 2003, was presented. The agency provided an overview of the Institute of Medicine report entitled "Ethical Conduct in Pediatric Clinical Trials." The committee was updated by the agency on the subpart D, institutional review board referral process. Agency action: The agency is taking the advisory committee recommendations under consideration.

09/30/2004

Date



Shalini Jain, PA-C, M.B.A.
Executive Secretary

**ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE
CENTER FOR DRUG EVALUATION AND RESEARCH**

CHAIR

James E. Leggett, Jr., M.D.
Expertise: Infectious Diseases
Term: 2/20/04 – 11/30/04
Associate Professor of Medicine
Oregon Health Sciences University
5050 NE Hoyt, Suite 540
Portland, Oregon 97213

CHAIR

Ellen R. Wald, M.D.
Expertise: Pediatric Infectious Diseases
Term: 02/23/00 – 11/30/03
Chief, Allergy, Immunology and Infectious Diseases
3705 Fifth Avenue at DeSoto Street
Pittsburgh, Pennsylvania 15213

EXECUTIVE SECRETARY

Tara P. Turner, Pharm.D.
Advisors and Consultants Staff
HFD-21
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857
(301)827-7001 Fax: (301)827-6776
E-mail: TurnerT@cder.fda.gov

MEMBERS

Alan S. Cross, M.D.
Expertise: Infectious Diseases
Term: 12/1/00 – 11/30/04
Professor of Medicine
University of Maryland
School of Medicine
Department of Medicine
Center for Vaccine Development
685 West Baltimore Street, Room 480
Baltimore, Maryland 21201

***Steven C. Ebert, Pharm.D.**
Expertise: Clinical Pharmacy
Term: 12/1/00 – 11/30/04
Department of Pharmacy
Meriter Hospital
202 South Park Street
Madison, Wisconsin 53715

Julio A. Ramirez, M.D.
Expertise: Infectious Diseases
Term: 12/1/00 – 11/30/04
Professor of Medicine
Chief, Division of Infectious Diseases
University of Louisville
512 South Hancock Street
Carmichael Bldg., Room 208-D
Louisville, Kentucky 40202

David M. Bell, M.D.
Expertise: Pediatric Infectious Diseases
Term: 4/23/02 – 11/30/05
Senior Medical Officer, Office of the Director
National Center for Infectious Diseases
Centers for Disease Control and Prevention
1600 Clifton Road, N.E. (Mail code C-12)
Atlanta, Georgia 30333

Mary P. Glodé, M.D.
Expertise: Pediatric Infectious Diseases
Term: 4/23/02 – 11/30/05
Professor of Pediatrics
The Children's Hospital of Denver
University of Colorado Health Sciences Center
1056 East Nineteenth Avenue (B158)
Denver, Colorado 80218

Celia J. Maxwell, M.D.
Expertise: Infectious Diseases
Term: 4/23/02 – 11/30/05
Assistant Vice President for Health Affairs
Howard University
Suite 6000
2041 Georgia Avenue, N.W.
Washington, D.C. 20060

Jan E. Patterson, M.D.
Expertise: Infectious Diseases
Term: 4/23/02 – 11/30/05
Audie L. Murphy Veterans Hospital
Chief, Medical Service 111
7400 Merton Minter Blvd.
San Antonio, Texas 78248

Ciro V. Sumaya, M.D.
Expertise: Pediatric Infectious Diseases
Term: 4/23/02 – 11/30/05
Dean, School of Rural Public Health
Texas A&M University System Health Science Center
3000 Briarcrest Drive, Suite 310
Mail stop 1266
Bryan, Texas 77802

Joan F. Hilton, Sc.D., M.P.H.

Expertise: Biostatistics
Term: 2/20/04 – 11/30/05
Associate Professor of Biostatistics in Residence
Department of Epidemiology and Biostatistics
University of California, San Francisco
500 Parnassus Avenue
San Francisco, California 94143

John S. Bradley, M.D.

Expertise: Pediatric Infectious Diseases
Term: 2/13/03 – 11/30/06
Director, Division of Infectious Diseases
Children's Hospital and Health Center
3020 Children's Way, MC 5041
San Diego, California 92123

Donald M. Poretz, M.D.

Expertise: Infectious Diseases
Term: 2/13/03 – 11/30/06
Infectious Diseases Physicians, Inc.
3289 Woodburn Road, #200
Annandale, Virginia 22003

****Samuel D. Maldonado, M.D., M.P.H.**

Expertise: Industry Representative
Term: 2/2/04 – 10/31/07
Senior Director, Global Regulatory Affairs
Johnson & Johnson Pharmaceutical Research
and Development L.L.C.
920 Route 202 South
Raritan, New Jersey 08869

John E. Edwards, Jr., M.D.

Expertise: Infectious Diseases
Term: 2/20/04 – 11/30/07
Chief, Division of Infectious Diseases
Harbor-UCLA Medical Center
Saint Johns Cardiovascular Research Center
1124 W. Carson Street
Torrance, California 90502

***Consumer Representative**

****Industry Representative**